{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:40:58Z","timestamp":1785883258962,"version":"3.56.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019284","name":"University of Hawai\u2032i Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While metabolic dysfunction-associated steatotic liver disease (MASLD) has become increasingly prevalent worldwide, multi-ethnic differences within a shared geography and lifestyle, have not been fully examined. What remains poorly characterized are the clinical outcomes for ethnic minorities in the U.S., particularly Asians and Native Hawaiian and Pacific Islanders (NHPI), compared with White people\/persons\/person.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults (aged \u226518 years) diagnosed with MASLD between January 2008 and December 2018 were identified in the TriNetX national database using the ICD-10 codes and followed outcomes through August 2025. Propensity score matching was conducted to compare Asians and NHPI with White people\/persons\/person with MASLD, adjusting for age, gender, body mass index, hypertension, type 2 diabetes, hyperlipidemia, and smoking status. Hazard ratios (HR) with 95% confidence intervals were estimated for the major outcomes: all-cause mortality, cirrhosis, and hepatocellular carcinoma (HCC). The effects of extrahepatic diseases related to metabolic diseases, such as myocardial infarction (MI), heart failure (HF), chronic kidney disease (CKD), and non-HCC cancer, were examined in the analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 188,328 White, 14,475 Asian, and 2,390 NHPI patients living in the U.S. (United States of America) with MASLD were identified with a median follow-up of over 8 years. After propensity score matching, Asian and NHPI demonstrated significantly lower rates of cirrhosis than White people\/persons\/person. In Asians, the risk of HCC increased with longer follow-up period, and with \u22655 years of follow-up, HCC risk significantly exceeded that of White people\/persons\/person. Asians had lower rates of CKD, MI, HF, and non-HCC cancers than White people\/persons\/person. NHPI had a significantly lower rate of non-HCC cancers but a higher risk of CKD compared with White people\/persons\/person. All-cause mortality was lower among Asians, but not in NHPI, compared with White people\/persons\/person.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a large, multiethnic U.S. cohort of MASLD, Asians and NHPI showed distinct outcome profiles. Ethnicity-tailored MASLD management strategies should be further explored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1739137","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:05Z","timestamp":1767940805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes"],"prefix":"10.3389","volume":"16","author":[{"given":"Yusuke","family":"Miyatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Sempokuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Shikuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Kuwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.001","article-title":"Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden","volume":"83","author":"Issa","year":"2025","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0205","article-title":"Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study","volume":"29","author":"Nguyen","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and Malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA","volume":"72","author":"Vitale","year":"2023","journal-title":"LI.CA database. Gut"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0324","DOI":"10.1097\/HC9.0000000000000324","article-title":"Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States","volume":"7","author":"Ochoa-Allemant","year":"2023","journal-title":"Hepatol Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.038","article-title":"Disparities for hispanic adults with metabolic dysfunction-associated steatotic liver disease in the United States: A systematic review and meta-analysis","volume":"23","author":"Tesfai","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: A systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1981","article-title":"Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018","volume":"6","author":"Truong","year":"2022","journal-title":"Hepatol Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"bvad165","DOI":"10.1210\/jendso\/bvad165","article-title":"Prevalence study of MASLD in adolescent and young adult pacific islanders and asians living in hawai\u2019i","volume":"8","author":"Parsa","year":"2024","journal-title":"J Endocr Soc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ajerev\/mxp004","article-title":"Cardiometabolic health disparities in native Hawaiians and other Pacific Islanders","volume":"31","author":"Mau","year":"2009","journal-title":"Epidemiol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.42204","article-title":"Representation of native hawaiian and pacific islander individuals in clinical trials","volume":"7","author":"Taira","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2179864","article-title":"Association of aspirin with all-cause and cardiocerebrovascular mortality in patients with metabolic associated fatty liver disease","volume":"58","author":"Chen","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24726","article-title":"Ethnicity and nonalcoholic fatty liver disease","volume":"55","author":"Bambha","year":"2012","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1038\/nutd.2011.2","article-title":"Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index","volume":"1","author":"Lim","year":"2011","journal-title":"Nutr Diabetes"},{"key":"B24","first-page":"49","article-title":"Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort","volume":"19","author":"Maskarinec","year":"2009","journal-title":"Ethn Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jhep.2008.11.017","article-title":"Influence of ethnicity on histological differences in non-alcoholic fatty liver disease","volume":"50","author":"Mohanty","year":"2009","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0515","article-title":"Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study","volume":"30","author":"Iwaki","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047881","article-title":"Population genetic structure and origins of Native Hawaiians in the multiethnic cohort study","volume":"7","author":"Kim","year":"2012","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1751","article-title":"Association of genetic risk score with NAFLD in an ethnically diverse cohort","volume":"5","author":"Wang","year":"2021","journal-title":"Hepatol Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","article-title":"Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: A cohort study","volume":"69","author":"Chang","year":"2019","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000588","article-title":"Positive hepatitis B core antibody is associated with cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"115","author":"Chan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12981","article-title":"Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016","volume":"25","author":"Li","year":"2018","journal-title":"J Viral Hepat"},{"key":"B32","first-page":"e98","article-title":"Hepatitis B virus infection testing and prevalence among Asian and Pacific Islanders","volume":"20","author":"Vijayadeva","year":"2014","journal-title":"Am J Manag Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17710247","article-title":"Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area","volume":"10","author":"Shim","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101160","DOI":"10.1016\/j.jhepr.2024.101160","article-title":"MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis","volume":"6","author":"Vitellius","year":"2024","journal-title":"JHEP Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cgh.2020.06.066","article-title":"Lean americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases","volume":"19","author":"Weinberg","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14038","article-title":"Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States","volume":"39","author":"Golabi","year":"2019","journal-title":"Liver Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2020.01.008","article-title":"Incidence of ESKD among native hawaiians and pacific islanders living in the 50 US states and pacific island territories","volume":"76","author":"Xiang","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-22-1291","article-title":"Associations of race and ethnicity with hepatocellular carcinoma, decompensation, and mortality in US veterans with cirrhosis","volume":"32","author":"VoPham","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Barba","year":"2004","journal-title":"Lancet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1739137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:06Z","timestamp":1767940806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1739137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":41,"alternative-id":["10.3389\/fendo.2025.1739137"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1739137","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1739137"}}